Australia is closely awaiting the arrival of retatrutide, a groundbreaking dual GIP and GLP-1 receptor agonist that's generating significant buzz in the global weight management landscape. Developed by Novo Nordisk, https://anyaauez449189.topbloghub.com/49433351/retatrutide-australia-a-potential-breakthrough-for-obesity-treatment